GLTO – Webcast to review Topline Data GULLIVER-2 Trial

The data being presented is Phase 1/2 data, which is very pre-liminary, which in this case is a good thing. Catalyst traders love when “rumors” can take over the psychology of traders. And positive Phase 1/2 data is certainly a rumor-fueler. It isn’t efficacy or even really safety, which means the company and traders alike can make inferences from this data about those other important things they will test in further studies.

In the past, there have been a lot of companies that run pretty big when positive, early-stage data is presented. The key here is traders need to make sure that the data presentation day is the same day the data will be released. We will update if we find out specifically. We have emailed the IR team at GLTO for answers.

Link to event PR: https://www.biospace.com/article/releases/galecto-to-host-virtual-investor-event-and-webcast-to-review-topline-data-from-gulliver-2-trial-on-tuesday-november-8-2022/